ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,905
-0,12%
Bitcoin
64 877,09
0,09%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) Actualités

NBIX Neurocrine Biosciences Inc

134,07
3,21 (2,45%)
21 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Neurocrine Biosciences Inc NBIX NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
3,21 2,45% 134,07 01:22:43
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
129,99 129,33 135,19 134,07 130,86
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
04/6/202422:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202414:01PRNUSNeurocrine Biosciences Presented CAHtalyst™ Phase 3..
03/6/202413:35PRNUSNeurocrine Biosciences Announces Publication of Primary..
03/6/202413:30PRNUSNeurocrine Biosciences Announces Publication of Primary..
30/5/202422:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:53EDGAR2Form 144 - Report of proposed sale of securities
29/5/202422:01PRNUSNeurocrine Biosciences to Participate at Investor..
28/5/202422:14PRNUSNeurocrine Biosciences Announces CEO Succession Plan
28/5/202414:30PRNUSNeurocrine Biosciences to Present New Phase 3 CAHtalyst™..
24/5/202400:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/5/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202423:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202422:01EDGAR2Form 8-K - Current report
21/5/202423:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202422:05PRNUSNeurocrine Biosciences Announces Publication of Phase 3..
17/5/202422:32EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:31EDGAR2Form 144 - Report of proposed sale of securities
17/5/202422:31EDGAR2Form 144 - Report of proposed sale of securities
16/5/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202422:23EDGAR2Form 144 - Report of proposed sale of securities
14/5/202422:23EDGAR2Form 144 - Report of proposed sale of securities
14/5/202414:30PRNUSNeurocrine Biosciences Presented Baseline Data from the..
09/5/202415:45PRNUSNeurocrine Biosciences Presents CAHtalyst™ Adult Study..
09/5/202414:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
08/5/202422:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202414:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
07/5/202422:15PRNUSNeurocrine Biosciences to Present at the BofA Securities..
07/5/202414:30PRNUSNeurocrine Biosciences to Present Phase 3 Baseline..
06/5/202414:30PRNUSNeurocrine Biosciences Supports Tardive Dyskinesia Awareness..
03/5/202419:15PRNUSNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study..
01/5/202413:00PRNUSNeurocrine Biosciences Reports First Quarter 2024 Financial..
30/4/202423:12PRNUSNeurocrine Biosciences Announces U.S. FDA Approval of..
24/4/202414:30PRNUSNeurocrine Biosciences Launches WHAT THE C@H?! Educational..
23/4/202413:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
16/4/202422:01GLOBESentia Medical Sciences and Neurocrine Biosciences Extend..
10/4/202422:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
03/4/202414:30PRNUSNeurocrine Biosciences Announces First-Patient Dosed in..

Dernières Valeurs Consultées

NASDAQ
NBIX
Neurocrine Biosciences
AQSE
SMS.GB
Smart Metering Systems
NASDAQ
SFR
Appreciate
ASX
MQR
Marquee Resources
BIT
I07248
INTESA SANPAOLO
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés